Medical devices, healthcare technology and the business of care
PMA approval · P160035

EXCOR Pediatric Ventricular Assist Device

Berlin Heart, Inc. · Decision date Jun 6, 2017

FDA DECISIONP160035

What did the FDA approve?

FDA records P160035 as an original PMA application. The recorded decision is approval, dated Jun 6, 2017.

FDA approval order statement

Approval for the EXCOR Pediatric Ventricular Assist Device (referred to as EXCOR Pediatric) is intended to provide mechanical circulatory support as a bridge to cardiac transplantation for pediatric patients. Pediatric candidates with severe isolated left ventricular or biventricular dysfunction who are candidates for cardiac transplant and require circulatory support may be treated using the EXCOR Pediatric.
Regulatory pathway
Original PMA
Clinical specialty
Cardiovascular
Decision date
Jun 6, 2017

FDA source record

Regulatory record facts

Identifier
P160035
Regulatory pathway
Premarket approval application
Product code
DSQ
Decision code
APPR
Decision date
Jun 6, 2017
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Ventricular (assist) bypass.

Product code
DSQ
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P160035 received

    Application receipt date recorded by FDA.

  2. P160035 · FDA decision

    APPR

  3. P160035/S058 · Related supplement

    EXCOR Pediatric Ventricular Assist Device

  4. P160035/S057 · Related supplement

    EXCOR Pediatric Ventricular Assist Device

  5. P160035/S060 · Related supplement

    EXCOR Pediatric Ventricular Assist Device

  6. P160035/S054 · Related supplement

    EXCOR Pediatric Ventricular Assist Device

Timeline entries are records held by MedtechLedger for P160035. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P160035

Product / regulatory recordCompanyPathwayDecision dateSource
Berlin Heart, Inc.PMA supplementSep 1, 2026FDA
Berlin Heart, Inc.PMA supplementOct 1, 2026FDA
Berlin Heart, Inc.PMA supplementOct 14, 2026FDA
Berlin Heart, Inc.PMA supplementOct 23, 2026FDA
Berlin Heart, Inc.PMA supplementOct 28, 2026FDA
Berlin Heart, Inc.PMA supplementOct 30, 2026FDA

Explore the linked device profile

Other records with product code DSQ

Product / regulatory recordCompanyPathwayDecision dateSource
AbbottPMA supplementOct 30, 2026FDA
ABBOTT MEDICALPMA supplementOct 19, 2026FDA
AbbottPMA supplementOct 2, 2026FDA
HeartMate II LVASP060040/S128
ABBOTT MEDICALPMA supplementOct 1, 2026FDA
HeartMate 3 LVASP160054/S135
ABBOTT MEDICALPMA supplementOct 1, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Berlin Heart, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
9391 Grogan'S Mill Rd., Suite A-6, The Woodlands, TX, 77380

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records